ACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingTipRanks Financial Blog • 25 days ago
Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on ACELYRIN, INC. (SLRN Research Report), reducing the price target to $28.00. Em...
Share to Feed
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023.
The post SLRN Stock...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with...
Avalo acquires Phase 2-ready anti-IL-1 mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical...
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and...